ADVIA Centaur EBV-VCA IgM
Epstein-Barr Virus, Other. 510(k) K233606, from Biokit, S.A. (Lliçà D’Amunt, Barcelona, ES). Product code LSE, class 1.
As of Nov 22, 2026, K233606 is an FDA 510(k) held by Biokit, S.A., substantially equivalent on Aug 7, 2024 after 272 days, with no recalls tied to it in FDA's recall database.
- Review time: 272 days
- Recalls: 0
The ADVIA Centaur EBV-VCA IgM (EBVM) assay is for in vitro diagnostic use in the qualitative detection of IgM antibodies to the viral capsid antigen (VCA) of the Epstein-Barr virus (EBV) in human pediatric (2-21 years old) and adult serum and plasma (EDTA and lithium heparin) using the ADVIA Centaur XP system.
- DiaSorin Liaison Ebna Igg, Liaison Vca Igg, Liaison Vca Igm AssaysK040120 · DiaSorin, Inc. · Apr 29, 2005
- Elecsys EBV EBNA IgGK260221 · Roche Diagnostics · Oct 2, 2026
- Elecsys EBV VCA IgGK260232 · Roche Diagnostics · Oct 2, 2026
- Document
- 510(k) summary (PDF) ↗
- Type
- Traditional
- Received
- Nov 9, 2023
- Review panel
- Microbiology
- Regulation
- 21 CFR 866.3235
One page per 510(k), De Novo and original PMA. Recalls are those FDA's recall database ties to this number; recalls of related devices that cite another number are not shown. Refreshed weekly. Predicates are read by Arca from the text of FDA's 510(k) summary PDFs, most of them scans: a device number counts when the summary names it as a predicate or as the device it is substantially equivalent to. About 97% of those read were right on a sample we checked by hand; summaries from before 2000 often name predicates without a number, so older devices show fewer. Pivotal studies are read by a model from FDA's De Novo decision summaries and PMA SSEDs; a count or result is shown only when its numbers appear in FDA's text. openFDA device 510(k), PMA and recall files